Últimas noticias sobre Bruker (NASDAQ:BRKR) Bolsa

BRUKER CORP

Bruker

Bruker Corp manufactures scientific instruments and diagnostic tests for customers in the life sciences, applied markets, pharmaceutical, and biotechnology industries. The company operates in segments, namely, Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Supercon Technologies (BEST). The company generates maximum revenue from the BSI CALID segment. Geographically, it derives the maximum of its revenue from United States.

Bruker Corp

News

Legal

BRKR

10x Genomics Reaches Patent Litigation Settlement With Bruker; Bruker To Pay $68M In Equal Quarterly Installments Between Q3 2025 And Q2 2026 As Well As Ongoing Royalties On Sales Of Spatial Biology Products Through Life Of Licensed Patents

Bruker And 10x Genomics Settle Patent Disputes And Enter Global Cross-License Agreement, Dismissing All Ongoing Litigations

The Federal Circuit rejects Bruker Cellular's invalidity challenge to AbCellera's patent for microfluidic devices and their use in culturing cells
AbCellera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABCL#NASDAQ">ABCL</a>) today announced that the United States Court of Appeals for the Federal Circuit (CAFC) has by a Rule 36 Order affirmed judgment of validity of its U.S. Patent No. 10,087,408 ("the ‘408 Patent"). AbCellera's ‘408 Patent is directed to microfluidic devices and using such devices to culture and selectively recover cells.
Previously Berkeley Lights Inc., now Bruker Cellular Analysis, Inc. (Bruker), a subsidiary of Bruker Corporation, challenged the claims of the ‘408 Patent alleging invalidity based on anticipation and obviousness over the prior art. The U.S. Patent Trial and Appeal Board (PTAB) rejected all of Bruker's arguments and now the CAFC has confirmed that all claims of AbCellera's ‘408 Patent are valid. AbCellera's ‘408 Patent is part of a multi-patent infringement litigation between AbCellera and Bruker pending in the U.S. District Court for the Northern District of California.

ABCL

AbCellera Announces The Federal Circuit Upholds Validity Of Its '408 Patent On Microfluidic Cell-Culturing Devices, Rejecting Bruker Cellular's Invalidity Challenge And Strengthening AbCellera's Position In Ongoing Patent Litigation.

UBS analyst Dan Leonard maintains Bruker (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRKR#NASDAQ">BRKR</a>) with a Neutral and lowers the price target from $57 to $45.

Price Target

Analyst Ratings

UBS Maintains Neutral on Bruker, Lowers Price Target to $45

Barclays analyst Luke Sergott maintains Bruker (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRKR#NASDAQ">BRKR</a>) with a Overweight and lowers the price target from $50 to $46.

Barclays Maintains Overweight on Bruker, Lowers Price Target to $46

Goldman Sachs analyst Matthew Sykes maintains Bruker (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRKR#NASDAQ">BRKR</a>) with a Neutral and lowers the price target from $50 to $45.

Goldman Sachs Maintains Neutral on Bruker, Lowers Price Target to $45

Stifel analyst Daniel Arias maintains Bruker (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRKR#NASDAQ">BRKR</a>) with a Hold and lowers the price target from $57 to $48.

Stifel Maintains Hold on Bruker, Lowers Price Target to $48

Bruker (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRKR#NASDAQ">BRKR</a>) lowers FY2025 Adj EPS guidance from $2.67-$2.72 to $2.40-$2.48 vs $2.61 analyst estimate. Raises FY2025 sales outlook from $3.47 billion-$3.54 billion to $3.48 billion-$3.55 billion vs $3.48 billion estimate.

Guidance

Bruker Lowers FY2025 Adj EPS Guidance from $2.67-$2.72 to $2.40-$2.48 vs $2.61 Est; Raises FY2025 Sales Guidance from $3.47B-$3.54B to $3.48B-$3.55B vs $3.48B Est

Bruker (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRKR#NASDAQ">BRKR</a>) reported quarterly earnings of $0.47 per share which beat the analyst consensus estimate of $0.43 by 9.3 percent. This is a 11.32 percent decrease over earnings of $0.53 per share from the same period last year. The company reported quarterly sales of $801.40 million which beat the analyst consensus estimate of $764.56 million by 4.82 percent. This is a 11.04 percent increase over sales of $721.70 million the same period last year.

Earnings

Earnings Beats

Bruker Q1 Adj. EPS $0.47 Beats $0.43 Estimate, Sales $801.40M Beat $764.56M Estimate

ACAD

ACDC

ACRE

ACVA

ADMA

ADNT

ADTN

AIRG

ALNT

ALTG

ALTO

ALVO

AMPH

AMPL

AMRK

AMRN

AOSL

APLS

ARIS

ARMN

ASLE

Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share

AVDL

AVDX

AXON

AXTA

AZTA

BAND

BBDO

BBGI

BBSI

BGSF

Brighthouse Financial, Inc. - Common Stock

BLBD

BLMN

BLZE

BMBL

BROS

BTMD

BXSL

BYND

CAPL

CCSI

CDLX

CENT

CENTA

CENX

CEVA

CIVI

CMTG

CNDT

COHR

Core Scientific, Inc. - Class A Common Stock

CORZ

CPRX

CRNC

CRNT

CSGS

CSTE

CTVA

CVNA

CYRX

Earnings Scheduled For May 7, 2025

Bruker Says It Will Showcase Major Spatial Biology And Multiomics Innovations At AACR 2025, Highlighting CosMx WTX And 1,200-Plex Protein Panel

Across the recent three months, 6 analysts have shared their insights on Bruker (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRKR#NASDAQ">BRKR</a>), expressing a variety of opinions spanning from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $57.0, with a high estimate of $65.00 and a low estimate of $50.00. Observing a downward trend, the current average is 17.39% lower than the prior average price target of $69.00. 
<img src="https://www.benzinga.com/files/images/story/2025/1744923614_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
The standing of Bruker among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Brandon Couillard &#x7C;Wells Fargo &#x7C;Lowers &#x7C;Overweight &#x7C; $60.00&#x7C;$75.00 &#x7C; 
&#x7C;Luke Sergott &#x7C;Barclays &#x7C;Lowers &#x7C;Overweight &#x7C; $50.00&#x7C;$60.00 &#x7C; 
&#x7C;Patrick Donnelly &#x7C;Citigroup &#x7C;Lowers &#x7C;Buy &#x7C; $50.00&#x7C;$75.00 &#x7C; 
&#x7C;Daniel Arias &#x7C;Stifel &#x7C;Lowers &#x7C;Hold &#x7C; $57.00&#x7C;$70.00 &#x7C; 
&#x7C;Luke Sergott &#x7C;Barclays &#x7C;Lowers &#x7C;Overweight &#x7C; $60.00&#x7C;$65.00 &#x7C; 
&#x7C;Luke Sergott &#x7C;Barclays &#x7C;Lowers &#x7C;Overweight &#x7C; $65.00&#x7C;$69.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Bruker. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Bruker compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Bruker's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Capture valuable insights into Bruker's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/BRKR/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Bruker analyst ratings.</a>
<h2>Delving into Bruker's Background</h2>
Bruker Corp manufactures scientific instruments and diagnostic tests for customers in the life sciences, applied markets, pharmaceutical, and biotechnology industries. The company operates in segments, namely, Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Supercon Technologies (BEST). The company generates maximum revenue from the BSI CALID segment. Geographically, it derives the maximum of its revenue from United States.
<h3>Key Indicators: Bruker's Financial Health</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Over the 3M period, Bruker showcased positive performance, achieving a revenue growth rate of 14.64% as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Bruker's net margin excels beyond industry benchmarks, reaching 1.4%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Bruker's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 0.76%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Bruker's ROA excels beyond industry benchmarks, reaching 0.23%. This signifies efficient management of assets and strong financial health.
Debt Management: Bruker's debt-to-equity ratio is notably higher than the industry average. With a ratio of 1.26, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Glimpse Into The Expert Outlook On Bruker Through 6 Analysts

Wells Fargo analyst Brandon Couillard maintains Bruker (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRKR#NASDAQ">BRKR</a>) with a Overweight and lowers the price target from $75 to $60.

Wells Fargo Maintains Overweight on Bruker, Lowers Price Target to $60

Bruker and RECIPE are pioneering the high-throughput ‘chrom-free' ClinDART triple-quad MS platform for robust and cost-effective therapeutic drug monitoring assays

Bruker Acquires Majority Stake In RECIPE to Advance Chrom-Free Triple-Quad Assays For Therapeutic Drug Monitoring

Bruker Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRKR#NASDAQ">BRKR</a>) reported preliminary revenue Friday for the first quarter that ended March 31, 2025, of $795 million to $800 million compared to a consensus of $758.85 million.
The company&#8217;s sales reflect around 10-11% year-over-year <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/b44759082/bruker-announces-first-quarter-2025-preliminary-revenue" rel="noreferrer noopener">increase from $721.70 million</a>.
Bruker Corporation is an American manufacturer of scientific instruments for molecular and materials research and industrial and applied analysis.
This estimated range implies a reported revenue growth of approximately 10% year over year, with low double-digit percentage constant exchange rate revenue growth.
Bruker estimates adjusted organic revenue growth in the first quarter to be in the low single-digit percentages, with mid-single-digit percentage organic revenue growth in the Bruker Scientific Instrument (BSI) segment and a high-teens percentage organic revenue decline in the Bruker Energy &amp; Supercon Technologies (BEST) segment, net of intercompany eliminations.
Concurrently, at the ESCMID Global 2025 conference, Bruker&#8217;s Microbiology and Infection Diagnostics division is announcing the expansion of its microbiology solutions into Next-Generation Sequencing (NGS) applications, with new, research-use-only NGS-based solutions in epidemiology and hospital-acquired infection (HAI) tracing.
On Friday, Bruker entered into a strategic collaboration with Ridom GmbH, based in Muenster, Germany, for NGS bioinformatics applications in microbiology <a href="https://www.benzinga.com/pressreleases/25/04/b44757010/bruker-complements-fast-cost-effective-ir-biotyper-hospital-hygiene-testing-and-hai-tracing-with-n" target="_blank" rel="noopener">and infectious disease testing</a>.
Ridom&#8217;s NGS bioinformatics software&nbsp;SeqSphere+&nbsp;is designed for genomic bacterial strain differentiation, multilocus sequence typing (MLST), core genome MLST (cgMLST), phylogenetic analysis, and real-time clonal and plasmid transmission detection.&nbsp;
SeqSphere+&nbsp;can handle data from various NGS instrument platforms. Financial details of the investment were not disclosed.
In October 2024, Bruker acquired Dynamic Biosensors GmbH, a biosensor development company <a target="_blank" href="https://www.benzinga.com/pressreleases/24/10/b41137534/bruker-acquires-dynamic-biosensors-a-pioneer-of-single-cell-interaction-cytometry-systems-for-drug" rel="noreferrer noopener">based in Munich, Germany</a>.
The acquisition strengthened Bruker&#8217;s biophysical portfolio for analyzing molecular interactions and kinetics.
Price Action: BRKR&#8217;s stock was up 2.47% at $39.01 during the premarket session on Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/04/44760665/blackrocks-bold-quarter-eps-tops-116t-aum-84b-inflows-power-growth" target="_blank" rel="noreferrer noopener">BlackRock&#8217;s Bold Quarter: EPS Tops, $11.6 Trillion AUM, $84 Billion Inflows Power Growth</a></li>
</ul>
Photo: Shutterstock

Large Cap

Health Care

Movers

Trading Ideas

General

Why Is Life Science Focused Bruker Stock Trading Higher On Friday?

WIIM

Bruker shares are trading higher after the company issued Q1 revenue guidance above consensus estimates and announced a partnership with Ridom for NGS bioinformatic applications.

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.bruker.com%2F&amp;esheet=54236894&amp;newsitemid=20250411651079&amp;lan=en-US&amp;anchor=Bruker+Corporation&amp;index=1&amp;md5=7b4923def2a7cf98f667d9ab0904355d">Bruker Corporation</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRKR#NASDAQ">BRKR</a>) today announced preliminary revenue for the first quarter ended March 31, 2025, in a range of $795 million to $800 million, comparing favorably to the Company's earlier outlook and well ahead of consensus.
This estimated range implies reported revenue growth of approximately 10% year-over-year, with low-double digit percentage constant exchange rate revenue growth. Bruker estimates non-GAAP organic revenue growth in the first quarter to be in the low-single digit percentages, with mid-single digit percentage organic revenue growth in the Bruker Scientific Instrument (BSI) segment, and a high-teens percentage organic revenue decline in the BEST segment, net of intercompany eliminations.
Bruker expects to report its first quarter 2025 financial results before market opening on May 7, 2025.

Bruker Sees Q1 Revenue Between $795M And $800M, Well Ahead Of Consensus

Bruker To Partner With Ridom For NGS Bioinformatics Applications In Microbiology And Infectious Disease Testing

Barclays analyst Luke Sergott maintains Bruker (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRKR#NASDAQ">BRKR</a>) with a Overweight and lowers the price target from $60 to $50.

Barclays Maintains Overweight on Bruker, Lowers Price Target to $50

Citigroup analyst Patrick Donnelly maintains Bruker (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRKR#NASDAQ">BRKR</a>) with a Buy and lowers the price target from $75 to $50.

Citigroup Maintains Buy on Bruker, Lowers Price Target to $50

Press Releases

Bruker Announces First-of-a-kind 1.3 GHz High-Resolution NMR System

Bruker Complements Fast, Cost-effective IR Biotyper® Hospital Hygiene Testing and HAI Tracing with NGS Reflex Testing

Bruker Announces First Quarter 2025 Preliminary Revenue

Bruker Announces Majority Acquisition of RECIPE, a Leading Provider of Mass Spectrometry-based Diagnostic Assay Kits for Therapeutic Drug Monitoring

Bruker Introduces nVista 2P Miniature Microscope

Management

Solis Agrosciences Names Crystal Winkeler Chief Business Officer to Drive Commercial Growth

Bruker to Launch Beacon Discovery™ at AACR 2025, Expanding Access to Live Single-Cell Functional Analysis

Bruker Spatial Biology Pushes Boundaries in Spatial Biology and Multiomics at AACR 2025

Bruker Reports First Quarter 2025 Financial Results

Bruker and 10x Genomics Reach Global Settlement of Patent Litigation

Agilent Technologies

Adaptive Biotechnologies Corporation - Common Stock

Adaptive Biotechnologies

Avantor

Azenta

Bio-Rad Laboratories, Inc. Class A Common Stock

Bio-Rad Laboratories

BioLife Solutions

Charles River Laboratories International, Inc. Common Stock

Charles River

Danaher

Evotec SE - American Depositary Shares each representing 1/2 of one ordinary share

Comments

Bruker

Noticias

Últimas noticias sobre Bruker (NASDAQ:BRKR) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL